ISRCTN87058979 https://doi.org/10.1186/ISRCTN87058979

A randomised study to compare the effectiveness of hyoscine hydrobromide (Hyoscine) and glycopyrronium (Robinul) in the management of noisy breathing/retained secretions in cancer patients

Submission date 12/09/2003	**Recruitment status** Stopped	[ ] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [ ] Record updated in last year
Registration date 12/09/2003	**Overall study status** Stopped	
Last Edited 04/01/2016	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Janet Hardy

Contact details
c/o Palliative Care
Mater Adult Hospital
Raymond Terrace
South Brisbane
Australia
Qld 4101

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0258107515

Study information

Scientific Title
A randomised study to compare the effectiveness of hyoscine hydrobromide (Hyoscine) and glycopyrronium (Robinul) in the management of noisy breathing/retained secretions in cancer patients

Study objectives
1. To compare the effectiveness of both hyoscine hydrobromide and glycopyrronium at relieving retained secretions at the time of death.
2. To test feasibility of the advanced 'consent process'.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Other

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Cancer: Noisy breathing, retained secretions

Interventions
Randomised test intervention versus standardised intervention, non-blinded (Phase 3).

Intervention Type
Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)
Hyoscine hydrobromide, glycopyrronium

Primary outcome measure
1. Provide an evidence base for common practice
2. Provide a means of obtaining consent for research in dying patients

Secondary outcome measures
Not provided at time of registration

Overall study start date
28/02/2002

Completion date
28/02/2005

Eligibility

Key inclusion criteria
Total number of Royal Marsden Hospital patients 205

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
205

Key exclusion criteria
Does not match inclusion criteria

Date of first enrolment
28/02/2002

Date of final enrolment
28/02/2005

Locations

Countries of recruitment
Australia

United Kingdom

Study participating centre
Mater Adult Hospital
South Brisbane
Australia
Qld 4101

Sponsor information

Organisation
Department of Health (UK)

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.doh.gov.uk

Funder(s)

Funder type
Charity

Funder Name
The Royal Marsden NHS Foundation Trust (UK) Charitable Funds

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration